Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GeparPiPPa
2022-501152-28-00Phase 2Authorised
- Sponsor
- GBG Forschungs
- Start
- Dec 2022
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 7
01
Overview
Phase 2, randomised, open-label trial of inavolisib and trastuzumab in breast cancer (2 arms), sponsored by GBG Forschungs. Primary endpoint: Pathological complete response. Planned start Dec 2022; status: authorised.
02
Drugs
inavolisibtrastuzumab
03
Conditions
breast cancer
Beyond the preview
Go deeper on 2022-501152-28-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-501152-28-00.